Post-effective amendment to a registration statement that is not immediately effective upon filing

Reverse Recapitalization (Details)

v3.22.1
Reverse Recapitalization (Details)
$ / shares in Units, $ in Thousands
12 Months Ended
May 24, 2021
$ / shares
shares
May 23, 2021
Dec. 31, 2021
USD ($)
$ / shares
shares
Dec. 31, 2020
USD ($)
Business Acquisition [Line Items]        
Deemed dividend - Earnout Shares | $     $ 253,130  
Earnout shares for common stockholders     22,209,280  
Earnout cash for common stockholders | $     $ 88,800  
Aggregate purchase price | $     $ 9,624 $ 2,579
Substitute Warrants        
Business Acquisition [Line Items]        
Contingent Consideration (in shares)     1,920,492  
Substitute Options        
Business Acquisition [Line Items]        
Contingent Consideration (in shares)     935,608  
Merger agreement        
Business Acquisition [Line Items]        
Exchange Ratio 3.16      
Contingent Consideration (in shares)     25,000,000  
Contingent Consideration | $     $ 100,000  
Number of business days for issue of Earnout shares     5 days  
Stock Issued During Period, Shares, New Issues     3,729,730  
Merger agreement | Subscription agreements        
Business Acquisition [Line Items]        
Issue price (in dollars per share) | $ / shares     $ 10.00  
Stock Issued During Period, Shares, New Issues     1,000,000  
Aggregate purchase price | $     $ 10,000  
Merger agreement | Stockholders of NeuroRx        
Business Acquisition [Line Items]        
Consideration (in shares) 50,000,000      
Issue price (in dollars per share) | $ / shares $ 0.001      
Exchange Ratio 3.16 4.96